磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路在肝胆恶性肿瘤发生发展中的作用

陈旭晓; 陈拥军

doi:10.3969/j.issn.1001-5256.2015.06.040

磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路在肝胆恶性肿瘤发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2015.06.040

上海交通大学医学院附属瑞金医院普外科

详细信息

中图分类号: R735.7;R735.8
计量
- 文章访问数: 2700
- HTML全文浏览量: 10
- PDF下载量: 504
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

PI3K / Akt / mTOR signaling pathway and malignant hepatobiliary tumors

摘要

摘要: 磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白（PI3K/Akt/m TOR）信号通路参与调节细胞代谢、生长、增殖、血管生成等多种重要生物过程,其高度激活的状态与多种恶性肿瘤的发生、发展相关。对PI3K/Akt/m TOR信号通路及m TOR蛋白进行了简单的介绍,并阐述了其在肝细胞癌、胆管细胞癌、胆管癌及胆囊癌发生发展中的作用机制,进一步简述了m TOR抑制剂在肝胆恶性肿瘤治疗中的作用。认为PI3K/Akt/m TOR信号通路为晚期肝胆恶性肿瘤提供了新的治疗靶点,新型m TOR抑制剂的不断研发将为晚期肝胆恶性肿瘤患者带来新的希望。
- 肝肿瘤 /
- 胆道肿瘤 /
- 衔接蛋白质类,信号转导 /
- 综述
Abstract: Phosphoinositide- 3 kinase / protein kinase- B / mammalian target of rapamycin( PI3 K / Akt / m TOR) signaling pathway is involved in many important biological processes such as cell metabolism,growth,proliferation,and angiogenesis. And its high- level activation is closely related to the development and progression of many malignant tumors. In this paper,m TOR and PI3 K / Akt / m TOR signaling pathway are introduced,and their action mechanisms in the development and progression of hepatocellular carcinoma,cholangiocellular carcinoma,cholangiocarcinoma,and gallbladder carcinoma are expounded,and then the role of m TOR inhibitors in the treatment of malignant hepatobiliary tumors is briefly described. It is thought that the PI3 K / Akt / m TOR signaling pathway provides new therapeutic targets for malignant hepatobiliary tumors in advanced stage and the constant development of new m TOR inhibitors provides some new hope for the patients with malignant hepatobiliary tumors in advanced stage.
- liver neoplasms /
- biliary tract neoplasms /
- adaptor proteins,signal transducing /
- review

HTML全文

参考文献(28)

[1] JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.

[2]FLORES A,MARRERO JA.Emerging trends in hepatocellular carcinoma:focus on diagnosis and therapeutics[J].Clin Med Insights Oncol,2014,8:71-76.

[3]ROA I,IBACACHE G,MUNOZ S,et al.Gallbladder cancer in Chile:Pathologic characteristics of survival and prognostic factors:analysis of 1,366 cases[J].Am J Clin Pathol,2014,141(5):675-682.

[4]MEMMOTT RM,DENNIS PA.Akt-dependent and-independent mechanisms of m TOR regulation in cancer[J].Cell Signal,2009,21(5):656-664.

[5]HWANG SK,KIM HH.The functions of m TOR in ischemic diseases[J].BMB Rep,2011,44(8):506-511.

[6]MARTINEZ-LOPEZ N,VARELA-REY M,FERNANDEZRAMOS D,et al.Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis[J].Hepatology,2010,52(5):1621-1631.

[7]WATANABE S,HORIE Y,SUZUKI A.Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma[J].Hepatol Res,2005,33(2):161-166.

[8]CALVISI DF,WANG C,HO C,et al.Increased lipogenesis,induced by AKT-m TORC1-RPS6 signaling,promotes development of human hepatocellular carcinoma[J].Gastroenterology,2011,140(3):1071-1083.

[9]MENON S,YECIES JL,ZHANG HH,et al.Chronic activation of m TOR complex 1 is sufficient to cause hepatocellular carcinoma in mice[J].Sci Signal,2012,5(217):ra24.

[10]SAHIN F,KANNANGAI R,ADEGBOLA O,et al.m TOR and P70S6 kinase expression in primary liver neoplasms[J].Clin Cancer Res,2004,10(24):8421-8425.

[11]VILLANUEVA A,CHIANG DY,NEWELL P,et al.Pivotal role of m TOR signaling in hepatocellular carcinoma[J].Gastroenterology,2008,135(6):1972-1983.

[12]NAKANISHI K,SAKAMOTO M,YAMASAKI S,et al.Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma[J].Cancer,2005,103(2):307-312.

[13]ZHOU L,HUANG Y,LI J,et al.The m TOR pathway is associated with the poor prognosis of human hepatocellular carcinoma[J].Med Oncol,2010,27(2):255-261.

[14]MCKAY SC,UNGER K,PERICLEOUS S,et al.Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma[J].HPB(Oxford),2011,13(5):309-319.

[15]LEE D,DO IG,CHOI K,et al.The expression of phospho-AKT1and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas[J].Mod Pathol,2012,25(1):131-139.

[16]WANG Z,ZHENG T,WU Q,et al.Immunohistochemical analysis of the m TOR pathway in intrahepatic cholangiocarcinoma[J].Neoplasma,2012,59(2):137-141.

[17]CHUNG JY,HONG SM,CHOI BY,et al.The expression of phospho-AKT,phospho-m TOR,and PTEN in extrahepatic cholangiocarcinoma[J].Clin Cancer Res,2009,15(2):660-667.

[18]HERBERGER B,PUHALLA H,LEHNERT M,et al.Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma[J].Clin Cancer Res,2007,13(16):4795-4799.

[19]LEAL P,GARCIA P,SANDOVAL A,et al.AKT/m TOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines[J].Onco Targets Ther,2013,6:1373-1384.

[20]LEAL P,GARCIA P,SANDOVAL A,et al.Immunohistochemical expression of phospho-m TOR is associated with poor prognosis in patients with gallbladder adenocarcinoma[J].Arch Pathol Lab Med,2013,137(4):552-557.

[21]ZHU AX,ABRAMS TA,MIKSAD R,et al.Phase 1/2 study of everolimus in advanced hepatocellular carcinoma[J].Cancer,2011,117(22):5094-5102.

[22]MASUDA M,SHIMOMURA M,KOBAYASHI K,et al.Growth inhibition by NVP-BEZ235,a dual PI3K/m TOR inhibitor,in hepatocellular carcinoma cell lines[J].Oncol Rep,2011,26(5):1273-1279.

[23]THOMAS HE,MERCER CA,CARNEVALLI LS,et al.m TOR inhibitors synergize on regression,reversal of gene expression,and autophagy in hepatocellular carcinoma[J].Sci Transl Med,2012,4(139):139r-184r.

[24]TAM KH,YANG ZF,LAU CK,et al.Inhibition of m TOR enhances chemosensitivity in hepatocellular carcinoma[J].Cancer Lett,2009,273(2):201-209.

[25]OKADA T,SAWADA T,KUBOTA K.Rapamycin inhibits growth of cholangiocarcinoma cells[J].Hepatogastroenterology,2009,56(89):6-10.

[26]RIZELL M,ANDERSSON M,CAHLIN C,et al.Effects of the m TOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer[J].Int J Clin Oncol,2008,13(1):66-70.

[27]ZONG H,YIN B,ZHOU H,et al.Inhibition of m TOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition[J].Mol Biol Rep,2014,41(7):4507-4512.

[28]WU Q,KIGUCHI K,KAWAMOTO T,et al.Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model[J].Cancer Res,2007,67(8):3794-3800.

施引文献

资源附件(0)

访问统计